. 2014 May 14;9(5):e97800. doi: 10.1371/journal.pone.0097800

Table 3. Coverage of dose 1, series completion, and timely dose 1 for Hib vaccine and PCV by sex, birth year and residency status of Shanghai children, 2012.

	Hib vaccine dose 1	Hib vaccine series completion^a	Hib vaccine timely dose 1^b	PCV dose 1	PCV series completion^a	PCV timely dose 1^b
	(n = 28,141)	(n = 14,316)	(n = 28,141)	(n = 28,141)	(n = 3,204)	(n = 28,141)
Overall	50.9%^**	79.7%^**	8.2%^**	11.4%^**	91.3%^**	0.5%^**
Sex
Male	51.2%^**	78.5%^**	7.8%^**	10.9%^**	91.8%^**	0.5%^**
Female	50.5%^**	81.0%^**	7.3%^**	12.0%^**	90.9%^**	0.5%^**
Birth cohort
2005–2007	48.9%^**	83.3%^**	4.4%^**	10.4%^**	97.3%^**	0.0%^**
2008–2010	53.2%^**	75.8%^**	11.3%^**	12.5%^**	82.5%^**	1.1%^**
Urbanicity
Urban	55.6%^**	81.6%^**	10.7%^**	14.3%^**	88.6%^**	0.8%^**
Suburban	48.6%^**	78.6%^**	6.1%^**	10.0%^**	93.1%^**	0.4%^**
Residency
Local	51.8%^**	85.4%^**	8.4%^**	14.7%^**	91.1%^**	0.9%^**
Floating	50.2%^**	75.4%^**	7.0%^**	9.1%^**	91.5%^**	0.2%^**

Hib: Haemophilus influenzae type b; PCV: 7-valent pneumococcal conjugate vaccine.

*P<0.05, chi-square test of homogeneity across demographic characteristic.

**P<0.0001, chi-square test of homogeneity across demographic characteristic or Fisher's Exact Test.

Series completion was calculated for only those children with dose 1; variable constructed from manufacturers' recommendations.

Timeliness was constructed from manufacturers' recommendations.